Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Global Ophthalmic Pipeline | Aerie Pharmaceuticals, Inc.
Aerie Pharma (AERI) Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Casey Kopczynski - Chief Scientific Officer and Founder - Aerie Pharmaceuticals, Inc | LinkedIn
Aerie Pharma Reports Mixed Bag On Phase 2 Dry Eye Trial
Déjà vu: Aerie Announces Mercury 2 Results, Stock Jumps - Ophthalmology Innovation Summit - OIS
Aerie Pharmaceuticals Inc 2021 Current Report 8-K
Aerie Pharma (AERI) Falls on Glaucoma Eye Drop Safety Concerns - TheStreet
Xconomy: Aerie Pharma Eyes $58M IPO For Glaucoma Drug Push
Aerie Pharma leaps on positive Ph III efficacy results for Rhopressa
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Aerie Looks to Japanese Market for Eye Drug, Opens Tokyo Office | North Carolina Biotechnology Center
Research & Development | Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Analysts Offer Insights on Healthcare Companies: Cooper Co (NYSE: COO) and Aerie Pharma (NASDAQ: AERI) - Markets
Aerie Pharma appoints Richard Rubino as CFO
Investor Relations | Aerie Pharmaceuticals, Inc
Investor Relations | Aerie Pharmaceuticals, Inc
Aerie Pharma on go with mid-stage study of eye drop for dry eye (NASDAQ:AERI) | Seeking Alpha
Working at Aerie Pharmaceuticals | Glassdoor
AeriePharma (@AeriePharma) | Twitter
Aerie Pharmaceuticals Employees, Location, Careers | LinkedIn
Aerie Pharmaceuticals and Ramot at Tel Aviv University Enter Research Collaboration | Business Wire
